Substrate Reduction Augments the Efficacy of Enzyme Therapy in a Mouse Model of Fabry DiseaseJohn Marshall(Genedata (Switzerland)), Seng H. Cheng(Pfizer (United States))PLoS ONENovember 24, 201010.1371/journal.pone.0015033Cited by 72SaveCiteExport RISWatch citationsRelated PapersInhibiting Glycosphingolipid Synthesis Improves Glycemic Control and Insulin Sensitivity in Animal Models of Type 2 Diabetes|Diabetes|2007|239Correction: Impairment of TrkB-PSD-95 Signaling in Angelman Syndrome|PLoS Biology|2013|24